Table 1.
Baseline demographic characteristics of the subjects included in the descriptive analysis.
| Study | Location | Age (years) | N | Females | JEV+ | DENV− | DENV+ monotypic | DENV+ multitypic |
|---|---|---|---|---|---|---|---|---|
| T1 | Philippines | 1.1 (1.0, 1.2) | 116 | 53 (46%) | 6 (5%) | 61 (53%) | 44 (38%) | 11 (9%) |
| T2 | Latin America | 12.6 (9.4, 16.2) | 361 | 187 (52%) | – | 91 (25%) | 55 (15%) | 215 (60%) |
| T3 | Vietnam | 10.8 (3.1, 28.3) | 113 | 59 (52%) | 42 (37%) | 34 (30%) | 37 (33%) | 42 (37%) |
| T4 | Thailand | 8.3 (4.9, 11.0) | 188 | 108 (57%) | 151 (80%) | 55 (29%) | 51 (27%) | 82 (44%) |
| T5 | Brazil | 12.7 (9.3, 16.3) | 89 | 52 (58%) | – | 26 (29%) | 14 (16%) | 49 (55%) |
Note: Study denotes the trail identifier; Location denotes the location where the trial was conducted, i.e. the country if the trial was single-site or the region if the trial was multicentre; Age denotes the observed mean and 5–95 percentiles of the age of the subjects included in the analysis in years; N denotes the number of subjects; JEV+ denotes subjects with titre against JEV ≥ 10; DENV− denotes subjects with titres < 10 for all four DENV serotypes; DENV+ denotes subjects with titres ≥ 10 for at least one DENV serotype; monotypic denotes subjects with titres ≥ 10 for one DENV serotype only or more than one DENV serotype with a titre ≥ 80 to only one DENV serotype; multitypic denotes subjects with titres ≥ 10 for at least two DENV serotypes without titre ≥ 80 to only one DENV serotype. The percentages within parentheses are computed on the number of subjects in each study (N). All titres have been quantified using PRNT50.